Lipoprotein(a) and treatment of chronic renal disease

J Intern Med. 1993 Nov;234(5):453-5. doi: 10.1111/j.1365-2796.1993.tb00777.x.

Abstract

Objectives: To compare lipoprotein(a) [Lp(a)] and albumin concentrations in patients with chronic renal disease receiving different forms of treatment and to determine, if any, the relationship between these variables.

Design: A prospective cross-sectional, case-controlled study.

Setting: A tertiary referral nephrology and dialysis unit.

Subjects: Forty-four consecutive non-diabetic patients with chronic renal failure treated by renal transplantation (n = 18), haemodialysis (n = 18), continuous ambulatory peritoneal dialysis (CAPD; n = 8), and 30 healthy controls from subjects drawn from University personnel were studied.

Interventions: Fasting morning venous blood was analysed for Lp(a), albumin, total cholesterol and glucose concentrations.

Main outcome measures: Comparison of plasma levels of these variables between the sub-groups.

Results: Concentrations (median; 95% CI) of Lp(a) were significantly (P < 0.05) higher (38.4 mg dl-1; range 15.4-72.0) and of albumin lower (31.6 g l-1; range 28-35.2) in the CAPD group compared with both control subjects and other groups of chronic renal disease patients.

Conclusions: The elevated Lp(a) concentrations seen only in association with reduced albumin concentrations in CAPD patients suggest a regulatory role for albumin with albumin losses stimulating production of Lp(a).

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Case-Control Studies
  • Cross-Sectional Studies
  • Female
  • Humans
  • Kidney Failure, Chronic / blood*
  • Kidney Failure, Chronic / therapy
  • Kidney Transplantation*
  • Lipoprotein(a) / blood*
  • Male
  • Middle Aged
  • Peritoneal Dialysis, Continuous Ambulatory*
  • Prospective Studies
  • Renal Dialysis*

Substances

  • Lipoprotein(a)